WAM
ACRS icon

Wealthspire Advisors (Maryland)’s Aclaris Therapeutics ACRS Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-103
Closed -$1K – 2414
2018
Q3 		$1K Buy
+103
New +$1.76K ﹤0.01% 2248

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ACRS Position: Q4 2018 in Review

Wealthspire Advisors (Maryland) sold out of Aclaris Therapeutics (ACRS) in Q4 2018, closing a stake of 103 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in ACRS in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 99 funds tracked by Wall St. Rank hold ACRS as of Q4 2018.

  • Wealthspire Advisors (Maryland) reported no remaining Aclaris Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 103 Aclaris Therapeutics shares in Q4 2018, an estimated $1K.
  • Wealthspire Advisors (Maryland) first reported a position in Aclaris Therapeutics in Q3 2018 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Aclaris Therapeutics position peaked at $1K in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2018.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q4 2018, filed 14 Feb 2019.